Non-Hodgkin Lymphoma

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.

The European Commission has granted conditional marketing authorization to epcoritamab for patients with relapsed or refractory follicular lymphoma.